Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”

Saved in:
Bibliographic Details
Main Authors: M. Costes-Albrespic, N. Alencar de Pinho, Z.A. Massy, S. Liabeuf
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024925003523
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849708343992516608
author M. Costes-Albrespic
N. Alencar de Pinho
Z.A. Massy
S. Liabeuf
author_facet M. Costes-Albrespic
N. Alencar de Pinho
Z.A. Massy
S. Liabeuf
author_sort M. Costes-Albrespic
collection DOAJ
format Article
id doaj-art-fa97ca780e3e45cc9036db65db11aab1
institution DOAJ
issn 2468-0249
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-fa97ca780e3e45cc9036db65db11aab12025-08-20T03:15:42ZengElsevierKidney International Reports2468-02492025-08-011082877287810.1016/j.ekir.2025.05.048Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”M. Costes-Albrespic0N. Alencar de Pinho1Z.A. Massy2S. Liabeuf3Clinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Villejuif, FranceClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Villejuif, France; Correspondence: Natalia Alencar de Pinho, Hôpital Paul Brousse, 16, avenue Paul Vaillant Couturier, F-94807 Villejuif, France.Clinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Villejuif, France; Association pour l'Utilisation du Rein Artificiel, Paris, France; Nephrology Department, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, ParisPharmaco-epidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Centre, Amiens, France; MP3CV Laboratory, Jules Verne University of Picardie, Amiens, Francehttp://www.sciencedirect.com/science/article/pii/S2468024925003523
spellingShingle M. Costes-Albrespic
N. Alencar de Pinho
Z.A. Massy
S. Liabeuf
Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
Kidney International Reports
title Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
title_full Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
title_fullStr Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
title_full_unstemmed Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
title_short Response to the Letter to the Editor Entitled “Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits”
title_sort response to the letter to the editor entitled optimizing furosemide use in advanced ckd balancing risks and benefits
url http://www.sciencedirect.com/science/article/pii/S2468024925003523
work_keys_str_mv AT mcostesalbrespic responsetothelettertotheeditorentitledoptimizingfurosemideuseinadvancedckdbalancingrisksandbenefits
AT nalencardepinho responsetothelettertotheeditorentitledoptimizingfurosemideuseinadvancedckdbalancingrisksandbenefits
AT zamassy responsetothelettertotheeditorentitledoptimizingfurosemideuseinadvancedckdbalancingrisksandbenefits
AT sliabeuf responsetothelettertotheeditorentitledoptimizingfurosemideuseinadvancedckdbalancingrisksandbenefits